stockrow
Friday 6 November 2026
Export WGS’s income statement to Excel — free account
GeneDx Holdings Corp.
WGS Healthcare Diagnostics & Research
GeneDx Holdings Corp.’s revenue for fiscal 2025 (year ended December 2025) was $427.5 million, up 40.0% from fiscal 2024.
- Revenue
- +11.4%
- EPS
- −257.9%
- Free cash flow
- −585.6%
- Total debt
- +87.4%
Quarter to June 2026, against a year earlier
64.89
4.45
−6.42%
Follow WGS
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | 196 | 179 | 212 | 235 | 203 | 305 | 428 | 454 | +13.9% | 482 | 599 | 728 | +19.4% | |
| Gross margin, % | — | — | — | 42.20 | 2.25 | (7.82) | (11.40) | 44.43 | 63.64 | 69.74 | 69.37 | +27.5 pt | ||||||
| EBT | — | — | — | (30) | (241) | (245) | (598) | (177) | (53) | (21) | (106) | (5.5%) | ||||||
| EBT margin, % | — | — | — | (15.14) | (134.58) | (115.64) | (254.81) | (87.23) | (17.23) | (4.94) | (23.39) | +10.2 pt | ||||||
| Net income | — | 0 | — | (30) | (241) | (245) | (549) | (176) | (52) | (21) | (106) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 1,153,344.48 | 64.80 | 22.93 | 8.33 | 11.36 | 14.93 | 15.30 | n/m | |||||
| Earnings | — | — | — | (7,905,874.00) | (1,552,177.00) | (74.92) | (53.79) | (7.23) | (1.94) | (0.73) | (3.64) | (93.3%) | ||||||
| Cash flow | — | — | — | 0.00 | (598,970.93) | (58.15) | (31.18) | (7.41) | (1.06) | 1.16 | (1.64) | n/m | ||||||
| Capex | — | — | — | 0.00 | (205,647.03) | (6.35) | (1.40) | (0.07) | (0.20) | (0.66) | (0.91) | n/m | ||||||
| Free cash flow | — | — | — | 0.00 | (804,617.96) | (64.50) | (32.58) | (7.48) | (1.26) | 0.50 | (2.55) | n/m | ||||||
| Book value | — | — | — | 0.00 | 28,222.28 | 118.52 | 24.78 | 9.38 | 9.12 | 10.76 | 8.22 | n/m | ||||||
| Shares, m | — | — | — | 0 | 0 | 3 | 10 | 24 | 27 | 29 | 29 | n/m | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | 0.00 | 0.00 | 0.07 | 0.01 | 0.32 | 6.77 | 8.71 | 4.24 | 2.3 | ||||||
| P/B | — | — | — | 0.00 | 1.43 | 0.04 | 0.01 | 0.28 | 8.43 | 12.09 | 7.89 | 3.2 | ||||||
| EV/Sales | — | — | — | 0.00 | 0.00 | (1.77) | (0.49) | (0.07) | 6.47 | 8.43 | 4.16 | 1.8 | ||||||
| EV/FCF | — | — | — | 0.00 | 0.00 | 1.78 | 0.34 | 0.07 | (58.19) | 252.56 | (24.96) | 28.1 | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (19) | (93) | (190) | (319) | (180) | (28) | 33 | (49) | n/m | |||||
| Capex | — | — | — | (15) | (32) | (21) | (14) | (2) | (5) | (19) | (27) | +3.5% | ||||||
| Free cash flow | — | — | — | (34) | (125) | (211) | (333) | (182) | (34) | 14 | (76) | n/m | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 101 | 382 | 68 | 124 | 143 | 159 | 172 | +9.6% | |||||
| Net debt | — | — | — | — | (68) | (390) | (118) | (77) | (89) | (123) | (36) | +12.5% | ||||||
| Shareholders’ equity | — | — | — | — | 4 | 388 | 254 | 228 | 245 | 308 | 244 | +134.0% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | 0.00 | (191.81) | (60.91) | (105.06) | (38.64) | (12.48) | (4.46) | (22.50) | (4.5) pt | |||||
| ROIC | — | — | — | 0.00 | 0.00 | 0.00 | (306.78) | (74.97) | (9.30) | (4.42) | (27.70) | (4.4) pt | ||||||
| ROE | — | — | — | 0.00 | (831.46) | (845.41) | (171.07) | (72.97) | (22.10) | (7.60) | (40.80) | (7.6) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | 1,200 | 1,100 | 1,000 | 1,000 | 1,300 | — | +2.0% | |||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.00 | 0.18 | 0.21 | 0.20 | 0.31 | 0.33 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026
GeneDx Holdings Corp. vs peers in Diagnostics & Research (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ADPT Adaptive Biotechnologies Corporation | $4.3B | — (loss-making) | — (loss-making) | −10.72% (below 0%: shrinking) | −66.67% (below 0%: shrinking) | +201.86% (above 0%: growing) | 76.24% | (0.54%) | Compare |
| CDNA CareDx, Inc. | $4.0B | 30.9× | 36.2× | +39.29% (above 0%: growing) | +1,133.33% (above 0%: growing) | −68.62% (below 0%: shrinking) | 71.09% | 5.82% | Compare |
| NEO NeoGenomics, Inc. | $2.1B | — (loss-making) | — (loss-making) | +11.43% (above 0%: growing) | n/m | −3,724.21% (below 0%: shrinking) | 46.16% | (3.79%) | Compare |
| VCYT Veracyte, Inc. | $1.9B | 15.2× | 45.2× | +15.08% (above 0%: growing) | +62.50% (above 0%: growing) | −9.63% (below 0%: shrinking) | 70.58% | 10.92% | Compare |
| WGS GeneDx Holdings Corp. | $1.9B | — (loss-making) | — (loss-making) | +11.44% (above 0%: growing) | n/m | −585.59% (below 0%: shrinking) | 68.37% | (15.25%) | |
| PSNL Personalis, Inc. | $1.7B | — (loss-making) | — (loss-making) | +76.59% (above 0%: growing) | n/m | −15.54% (below 0%: shrinking) | 25.67% | (138.76%) | Compare |
| OPK OPKO Health, Inc. | $1.3B | — (loss-making) | — (loss-making) | −56.87% (below 0%: shrinking) | n/m | −3.40% (below 0%: shrinking) | 64.30% | (48.02%) | Compare |
| FRNM Freenome, Inc | $1.1B | — (loss-making) | — | — | n/m | +12.06% (above 0%: growing) | — | 0.00% | Compare |
| CSTL Castle Biosciences, Inc. | $1.0B | — (loss-making) | — (loss-making) | +23.90% (above 0%: growing) | n/m | +56.82% (above 0%: growing) | 76.75% | (2.65%) | Compare |
| Median of peers | $1.8B | — | — | +15.08% | +62.50% | −6.51% | 70.58% | (1.59%) |
Pay and ownership Proxy statement filed 30 April 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 13.55m | 43.35m | 1,494.01 |
| 2024 | 4.42m | 51.51m | 882.90 |
| 2023 | 3.50m | 545.95k | 31.59 |
Ownership
Directors and executive officers, together
25.17%
Keith Meister
12.71%
Entities affiliated with Corvex Management LP
12.60%
Eli D. Casdin
12.04%
Entities affiliated with Casdin Partners Master Fund, LP
11.93%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement
GeneDx Holdings Corp. (WGS) Latest News
2 Oct
7 Aug
4 Aug
3 Aug
5 May
WGS metrics, ten years each
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score